title: Anxiolytic-like effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in experimental mouse models of anxiety.
abstract: OBJECTIVE
  The present study was designed to investigate the anxiolytic activity of 6g, a novel serotonin type-3 receptor (5-HT3) receptor antagonist in experimental mouse models of anxiety.
  
  
  METHODS
  The anxiolytic activity of "6g" (1 and 2 mg/kg, intraperitoneally [i.p.]) was evaluated in mice by using a battery of behavioral tests of anxiety such as elevated plus maze (EPM), light-dark (L&D) box, hole board (HB), and open field test (OFT) with diazepam (2 mg/kg, i.p.) as standard anxiolytic. None of the tested dose of "6g" affects the base line locomotion.
  
  
  RESULTS
  The new chemical entity "6g" (2 mg/kg, i.p.) and diazepam (2 mg/kg, i.p.) significantly (P < 0.05) increased the percentage of time spent and number of entries in open arm in the EPM test. In the L&D test compound "6g" (2 mg/kg, i.p.) and diazepam (2 mg/kg, i.p.) significantly (P < 0.05) increased the total time spent in light compartment as well as number of transitions from one compartment to other. Compound "6g" (1 and 2 mg/kg, i.p.) and diazepam (2 mg/kg, i.p.) also significantly (P < 0.05) increased number of head dips, whereas significantly (P < 0.05) decreased the head dipping latency in HB test as compared to vehicle control group. In addition, 6g (2 mg/kg, i.p.) and diazepam (2 mg/kg, i.p.) significantly (P < 0.05) increased the ambulation scores (square crossed) in OFT and there was no significant effect of 6g (1 and 2 mg/kg, i.p.) and diazepam (2 mg/kg, i.p.) on rearing scores.
  
  
  CONCLUSIONS
  In conclusion, these findings indicated that compound "6g" exhibited an anxiolytic-like effect in animal models of anxiety.
authors.affiliation: Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Rajasthan, India.
authors.forename: Shvetank
authors.initials: S
authors.lastname: Bhatt
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Mahesh
authors.forename: Thangaraj
authors.initials: T
authors.lastname: Devadoss
authors.forename: Ankur Kumar
authors.initials: AK
authors.lastname: Jindal
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy* / Q000523:psychology; D001522:Behavior, Animal / Q000187:drug effects; D005106:Exploratory Behavior / Q000187:drug effects; D008297:Male; D051379:Mice; D010879:Piperazines / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use*
chemical_list: C586173:(4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone; D014151:Anti-Anxiety Agents; D010879:Piperazines; D011810:Quinoxalines; D058831:Serotonin 5-HT3 Receptor Antagonists
keywords: 5-HT3 receptor antagonist; Anxiety; elevated plus maze; hole-board; open field test